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Objective: Attention-deficit/hyperactivity disorder (ADHD) has been associated with 
dopaminergic imbalance and subtle volume reductions in the brain. Stimulants acutely enhance 
dopaminergic neurotransmission. Long-term effects of chronic manipulation of the dopaminergic 
system on brain structure remain poorly understood; they could be beneficial or unfavorable, and 
may be moderated by common genetic variants and/or age.  
Method: In a large observational cohort study (NADHD=316), we evaluated the effects of 
cumulative stimulant treatment, genotype (for DAT1 haplotype and DRD4 variants), and 
treatment-by-genotype interactions on striatal, frontal, and hippocampal volumes, as well as their 
interactions with age.  
Results: We found no main effects of treatment. Associations between treatment and bilateral 
frontal and left hippocampal volume depended on DRD4 genotype and age. At younger age and 
lower treatment-levels, but not at younger age and higher treatment levels, carriers of the DRD4 
7R-allele showed decreased frontal cortex volumes. At older age, both carriers and non-carriers 
showed lower frontal volumes irrespective of treatment history. Left hippocampal volume was 
similar to controls at average treatment levels, and increased with treatment only in carriers of the 
DRD4 risk allele and at younger age. No interaction effects were found in the striatum.  
Conclusions: Carriers of the DRD4 risk allele may at younger age be sensitive to cortical 
remodeling after stimulant treatment. The cross-sectional nature of our study warrants cautious 
interpretation of age effects. Our findings, although of small effect size, may ultimately 
















Attention-deficit/hyperactivity disorder (ADHD) has been associated with widespread 
subtle changes in brain structure. Total gray matter volume is reduced by 2-3% in children with 
ADHD compared to typically developing children, with more pronounced reduction and atypical 
age-related changes in the frontal-striatal system.1-4 The striatum and its frontal connections are 
rich in dopaminergic neurons, and ADHD symptoms are thought to, at least partially, stem from 
dopaminergic and noradrenergic imbalances.5 Stimulants such as methylphenidate enhance 
dopaminergic and noradrenergic neurotransmission by binding to the dopamine transporter, 
thereby inhibiting presynaptic dopamine reuptake, and increasing extracellular dopamine 
availability.6  
Long-term effects of stimulant treatment on the developing brain remain poorly 
understood. Although several studies have suggested fewer structural abnormalities in individuals 
with ADHD after long-term stimulant treatment,e.g.2,7 findings are equivocal. Meta-analyses 
found larger (thus more normative) striatal volumes in studies including a higher percentage of 
stimulant-treated patients compared to studies with lower percentages.1,4 However, recent large-
scale original studies did not find evidence of structural normalization in the striatum.3,8 In the 
frontal cortex, disproportionate cortical thinning has been found in non-treated children but not in 
stimulant-treated children with ADHD,7 while others have found reduced middle frontal cortex 
volumes in stimulant-treated compared to stimulant-naive patients.9 Prior analyses of the current 
sample found no treatment effects on frontal cortical thickness.10 Thus, conclusive evidence of 
long-term treatment effects on frontal-striatal brain structures is missing. 
Genetic make-up may predispose potential brain changes after stimulant treatment. The 
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contains a variable number of tandem repeat (VNTR) polymorphism influencing presynaptic 
dopamine transporter density, especially in the striatum where gene expression is high. The 9- 
and 10-repeat alleles are most frequently encountered in the population. In children and 
adolescents, the 10-repeat allele has been associated with increased risk of ADHD,11 smaller 
striatal volumes,12 and distinct striatal activity patterns,13,14 but not with clinical treatment 
response.15,16 Recent studies have performed association analyses based on a haplotype of the 
3’UTR VNTR and a second VNTR of the DAT1 gene located in intron 8.17 The 10-6 haplotype 
(10-repeat allele in the 3’UTR VNTR, 6-repeat allele in the intron 8 VNTR) has been identified 
as the risk haplotype for ADHD in children and adolescents,18 whereas the 9-6 haplotype has 
been associated with adult ADHD.19 Associations between the DAT1 haplotype, stimulant 
treatment, and brain structure have not yet been investigated.  
A second dopaminergic gene, the dopamine receptor D4 (DRD4) gene, encodes the 
postsynaptic dopamine D4 receptor, and is highly expressed in the frontal cortex and 
hippocampus.20,21 The 7-repeat allele of a VNTR in exon 3 (DRD4 7R) has been identified as the 
risk allele for ADHD, but has also been associated with better clinical outcome in late 
adolescence.22 In ADHD-enriched samples, carriers of the 7-repeat allele have shown reduced 
frontal cortex volume and thickness.22,23 Moreover, DRD4 genotype modulated prefrontal cortex 
activation during various tasks.24,25 In the current sample, DRD4 genotype and social 
environment together, but not DRD4 genotype alone, influenced prefrontal cortex activation 
during response inhibition (unpublished results). It has been suggested that the DRD4 
polymorphism may be linked to attention problems.26 Most treatment studies failed to predict 
clinical treatment response from DRD4 7R-carriership,e.g.27,28 although modest genotype-by-dose 
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With DAT1 and DRD4 genes affecting presynaptic dopamine transporters in the striatum 
and postsynaptic dopamine receptors in the frontal cortex and hippocampus, respectively, inter-
individual genetic differences may predispose treatment effects in these brain regions. 
Pharmacological neuroimaging studies have shown different acute striatal responses to 
methylphenidate in individuals with different DAT1 3’UTR genotypes.31,32 Furthermore, the 
dopaminergic system undergoes changes during development, hence long-term treatment and 
genetic effects on brain structure may be different at different ages. Rapidly developing brain 
regions are particularly sensitive to external influences such as stimulant exposure.33 Support for 
age-dependent long-term stimulant treatment effects comes from animal studies showing striatal 
volume reduction and hippocampal shape deformations after chronic juvenile exposure but not 
following treatment in adulthood.34,35 Long-term structural changes after stimulant treatment may 
reflect dopamine-dependent long-term plasticity, a process of structural remodeling to which the 
hippocampus is known to be particularly sensitive.36 Thus, differential neural susceptibility to 
acute methylphenidate effects may translate into differential sensitivity to long-term stimulant 
treatment effects on brain structure.  
Identifying sources of neural sensitivity to long-term treatment effects is important, and 
may ultimately influence therapeutic decisions. Here, we investigated associations between 
stimulant treatment, genetic predispositions, age, and brain structure. We hypothesized that 
stimulant treatment would be associated with larger (more normative) striatal volume, and that 
this association would be more pronounced in DAT1 10-6 risk haplotype carriers and at younger 
age. Second, we hypothesized that stimulant treatment would be associated with larger frontal 
and hippocampal volume, especially in DRD4 7R-allele carriers and at younger age. We 
investigated these hypotheses in a large cross-sectional sample of children, adolescents and 
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case-control differences in brain structure.3,10 Inter-individual differences in neural sensitivity to 
long-term treatment effects, due to age and/or genetic make-up, have not been addressed in prior 





Participants with ADHD (n=316, mean age=17.2 years, 69.3% male) and control 
participants (n=187, mean age=16.5 years, 52.4% male) were selected from the Dutch family-
based follow-up phase (NeuroIMAGE) of the International Multisite ADHD Genetics (IMAGE) 
study. The protocol included diagnostic interviews, questionnaires for participants, parents, and 
teachers, DNA collection, and a magnetic resonance imaging (MRI) session, taking place at two 
testing sites in The Netherlands (Amsterdam and Nijmegen). Informed consent was signed by 
participants ≥ 12 years and parents of participants < 18 years. The study was approved by the 
ethical committee of each site. ADHD diagnosis and type (inattentive, hyperactive/impulsive, or 
combined type), ADHD severity, and axis-I comorbidity were obtained from a diagnostic 
interview37 and Conners ADHD questionnaires,38-40 rated while participants were off-medication. 
Controls were required to have no first-degree relative with psychiatric problems, i.e., unaffected 
siblings of participants with ADHD were excluded. All participants were of European Caucasian 
descent. For a detailed description of inclusion and diagnostic criteria, see41. 
 
Treatment history 
Pharmacy transcripts and self/parent-report questionnaires were combined to assess 
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methylphenidate preparations and/or d-amphetamine preparations), a dose-by-age trajectory from 
age=0 to age at scan was reconstructed (Figure 1). The area under the curve equals cumulative 
stimulant intake. Cumulative intake was divided by participant’s age minus 2.3 (minimum 
stimulant start age within the cohort) to obtain an age-adjusted treatment variable (CSIADJ) in 
mg/year which was subsequently standardized into a z-score. One extreme outlier (ZCSI-ADJ>4) 
was excluded (details available online, S1). Since CSIADJ is a composite parameter capturing 
dose, start age, treatment duration, and time since last treatment, these alternative parameters 
were evaluated post-hoc.  
 
Genotyping 
DNA was extracted from blood or saliva samples (for details, see42). No deviations from 
Hardy-Weinberg Equilibrium were found (pDRD4=0.15, pDAT1-3’UTR=0.78, pDAT1-INTRON 8=0.55). 
DAT1 haplotypes were calculated using the HaPloStats package (R version 2.12.0).43 Participants 
with zero, one, or two copies of the DAT1 10-6 risk haplotype were distinguished. We performed 
pairwise testing to avoid imposing a linear model (0vs1 copy, 0vs2 copies, and 1vs2 copies). For 
the DRD4 7R-allele, we differentiated between non-carriers (0 copies) and carriers (1 or 2 
copies), in line with the literature. Allele frequencies are in Table 1.  
 
Magnetic Resonance Imaging 
MRI data was acquired on two 1.5T Siemens scanners (Siemens, Germany), equipped 
with product 8-channel phased-array head coils using equivalent acquisition parameters. The 
session consisted of multiple acquisitions, including two T1-weighted 3D-MPRAGE scans 
(TI=1000 ms, TR=2730 ms, TE=2.95 ms, FA=7°; 176 sagittal slices, 1x1x1 mm voxels). For 
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accepting only scans with no/mild distortions.44 For data quality and compatibility between sites, 
see41. 
Striatal and hippocampal volumes were obtained with FMRIB’s Integrated Registration 
and Segmentation Tool (FSL FIRST).45 As our hypothesis regarding treatment effects was the 
same across striatal structures, striatal volume was calculated as the sum of caudate nucleus, 
putamen, and nucleus accumbens volume; individual structures were evaluated only post-hoc. 
Frontal cortex volume was derived by multiplying cortical thickness and surface area of the 
medial and lateral orbitofrontal, inferior frontal, caudal and rostral medial frontal, superior 
frontal, and frontal pole cortex, reconstructed using the automated Freesurfer pipeline.46,47 Total 
brain volume (TBV) was acquired using SPM (VBM8.1 toolbox, http://dbm.neuro.uni-
jena.de/vbm/) as the sum of gray and white matter tissue probability maps. 
 
Analyses 
All analyses were performed separately for three regions of interest (ROI; striatum, 
frontal cortex, hippocampus) in two hemispheres (left, right). ROI volumes were predicted from 
CSIADJ, genotype (DAT1 haplotype for striatum, DRD4 genotype for frontal cortex and 
hippocampus), and CSIADJ-by-genotype interaction, in linear mixed effects models with 
covariates gender, site, age, age2, TBV, and a random intercept per family to correct for 
relatedness within the sample (‘initial models’; volume ~ α + β*covariates + β*CSIADJ + 
β*genotype + β*CSIADJ*genotype). Age and CSIADJ were standardized, such that main effects of 
the predictors of interest are conditional to average age and treatment; non-genotype effects are 
also conditional to a reference category, i.e., DAT1 10-6 homozygotes and DRD4 7R-carriers. 
Next, the initial models were extended to allow interactions with age (‘age-interaction 
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β*age*CSIADJ + β*age*genotype + β*age*CSIADJ*genotype + β*age2 *CSIADJ + 
β*age2*genotype + β*age2*CSIADJ*genotype). Non-significant interaction terms were dropped 
from the model one-by-one, each time eliminating the highest-level and least-predictive 
interaction term and re-estimating the regression coefficients. Predictors and covariates from the 
initial model and lower-level interaction terms conditional to significant higher-level interaction 
terms were never removed. Alpha was divided by six (α=0.05/3/2=0.008).  
Clinical variables associated with stimulant treatment (e.g., severity) may drive spurious 
associations between brain volume and CSIADJ. Therefore, each variable associated with CSIADJ 
was post-hoc evaluated as a potential confounder. First, the confounder (and its interactions with 
age and genotype) was tested in a model identical to the significant CSIADJ model. If significant, 
CSIADJ and the confounder (and their age- and genotype-interactions) were modeled 
competitively. The same procedure was adopted to disentangle treatment parameters contributing 
to CSIADJ, i.e., non-adjusted cumulative intake, active versus past treatment, start age, treatment 
duration, and time since last treatment. 
Case-control comparisons of subcortical volumes3 and frontal cortex structure10 have 
previously been reported. In the current study, controls served only to estimate reference 
volumes. All other analyses are based on participants with ADHD only. Since the full control 
sample differed from the ADHD sample in terms of age (MHC=16.5, MADHD=17.2), gender 
(MaleHC=52.4%, MaleADHD=69.3%), and site (NijmegenHC=38.5%, NijmegenADHD=56.3%), 
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The majority of participants with ADHD were male (n=219, 69%), and most had 
inattentive (n=141, 45%) or combined type ADHD (n=138, 44%). Age ranged from 8 to 28 years 
(M[SD]=17.2[3.4] years). Comorbidities included oppositional defiant disorder or conduct 
disorder (n=97, 31%), anxiety/depression (n=11, 4%), and tic disorders (n=3, 1%). Age-adjusted 
cumulative stimulant intake ranged from 0 mg/year (treatment-naïve, n=38, 12%) to 15766 
mg/year. Treatment start age ranged from 2.3 to 20.6 years, and 146 participants (46.2%) were on 
active stimulant treatment within three months prior to study participation. Figure 1 shows 
treatment trajectories over time per age quartile. At older age, more participants had ceased 
treatment. Eighty-one participants (25.6%) had been treated with non-stimulant psychoactive 
medication.  
CSIADJ was higher in participants with combined type compared to inattentive or 
hyperactive/impulsive type ADHD (p=0.001). Furthermore, CSIADJ was marginally associated 
with DAT1 10-6 haplotype (M1COPY>M0COPIES>M2COPIES, p=0.029). CSIADJ was not associated 
with parent-rated inattention or hyperactivity/impulsivity symptoms, IQ, SES, DRD4 genotype, 
comorbidity, or non-stimulant medication. As expected, CSIADJ correlated positively with 
treatment duration, and negatively with start age and time since last treatment, and was higher in 
participants on active treatment compared to those who had discontinued (details available 
online, S1). 
 
Striatal volume and DAT1 
Left striatal volume was reduced in participants with ADHD carrying one 10-6 risk allele 
compared to 10-6 homozygotes (M0COPIES=10.30 mL, M1COPY=9.89 mL, M2COPIES=10.14 mL; 
p1vs2=0.005, p0vs1=0.018, p0vs2=0.352; effect size β[95% confidence interval]1vs2=0.243[0.075-
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most pronounced in the left putamen (p=0.009) and accumbens (p=0.013), and less prominent in 
the caudate (p=0.090). Covariates site, gender, and age or age2 were not associated with striatal 
volume, but, as expected, total brain volume was (Table S2, available online). Participants with 
and without ADHD did not differ with regard to striatal volume (pLEFT=0.531; pRIGHT=0.531). 
Treatment (CSIADJ) was not associated with left or right striatal volume as a main effect, nor in 
interaction with DAT1 haplotype, age, or age2 (Table 2).  
 
Frontal cortex volume and DRD4 
In the initial models, neither CSIADJ, DRD4 genotype, not their interaction was associated 
with frontal cortex volume (Table 2; Table S2, available online). When age and age2 were 
allowed to interact with stimulant treatment and genotype in the age-interaction models, however, 
significant age2-by-CSIADJ-by-DRD4 interaction effects were found in both hemispheres 
(pLEFT=0.003, β[CI]=0.187[0.062-0.311]; pRIGHT<0.001, β[CI]=0.220[0.093-0.346]; Figure 2). At 
younger age (plotted at 1SD below the mean, 13.9 years), frontal cortex volume increased with 
increasing CSIADJ in carriers of the 7R-allele. No such association was found in carriers of the 
7R-allele at older age (plotted at 1SD above the mean, 20.5 years), nor in non-carriers at older or 
younger age. As a consequence of the three-way interactions, the lower-level age2-by-CSIADJ 
interaction effect reached significance as well, as did the age2-by-DRD4 interaction effect on 
right frontal cortex volume (Table 2).  
CSIADJ was higher in combined type ADHD compared to inattentive or 
hyperactive/impulsive type. Models were re-estimated replacing CSIADJ with ADHD-type. Age2-
by-ADHD-type-by-DRD4 reached nominal significance in both hemispheres for inattentive 
versus combined type ADHD (pLEFT=0.030, pRIGHT=0.045); when CSIADJ and ADHD-type (and 
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DRD4 interaction term remained significant (pLEFT=0.002, pRIGHT=<0.001), while the age2-by-
ADHD-type-by-DRD4 interaction term was marginally significant (inattentive versus combined 
type, pLEFT=0.011, pRIGHT=0.009; hyperactive/impulsive versus combined type, pLEFT=0.062, 
pRIGHT=0.044).  
Finally, frontal cortex volume was reduced in participants with ADHD compared to 
control participants at trend level (right: MADHD=81.53 mL, MCONTROL=82.78 mL; p=0.010; left: 
MADHD=82.24 mL, MCONTROL=83.11 mL; p=0.073). Volume reduction in the right frontal cortex 
was significant when compared to the matched control group (Table S3, available online). 
 
Hippocampus volume and DRD4 
Neither CSIADJ nor DRD4 genotype was associated with hippocampus volume in the 
initial models, and there were no CSIADJ-by-DRD4 interaction effects (Table 2). When treatment 
and genotype were allowed to interact with age in the age-interaction models, however, a 
significant age-by-CSIADJ-by-DRD4 interaction effect was found in the left hippocampus 
(p=0.008; β[CI]=0.323[0.086-0.561]; Figure 2). Irrespective of genotype, there was little 
association between CSIADJ and left hippocampal volume at older age, whereas at younger age a 
negative association was found in 7R-non-carriers and a positive association was found in 7R-
carriers. The association was strongest in the 7R-carriers and at younger age. A similar but non-
significant trend was found in the right hippocampus (pAGE-BY-CSIADJ-BY-DRD4=0.066).  
Age-by-ADHD-type-by-DRD4 (i.e., replacing CSIADJ by ADHD-type) was not associated 
with left hippocampal volume. Finally, participants with and without ADHD did not differ in 
hippocampal volume (pLEFT=0.838; pRIGHT=0.277). 
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In an attempt to disentangle treatment parameters contributing to CSIADJ, significant 
models were re-estimated replacing CSIADJ with non-adjusted cumulative dose, treatment 
duration, start age, current treatment (y/n), and time since last treatment. Age2-by-treatment-by-
DRD4 interaction effects on the frontal cortex, significant when the treatment parameter was 
CSIADJ, were not significant when the treatment parameter was start age (pLEFT=0.676, 
pRIGHT=0.924), time since last treatment (pLEFT=0.157, pRIGHT=0.064), or current treatment (y/n) 
(pLEFT=0.659, pRIGHT=0.259). By contrast, when CSIADJ was replaced by non-adjusted cumulative 
intake or treatment duration, the effect changed very little (non-adjusted CSI: pLEFT=0.003, 
pRIGHT=0.001; duration: pLEFT=0.009, pRIGHT=0.002). When CSIADJ and treatment duration were 
modeled competitively, neither of the interaction terms reached significance, suggesting that the 
effects of CSIADJ and treatment duration at least partially overlap.  
In the left hippocampus, replacing CSIADJ by non-adjusted cumulative dose, treatment 
duration, or start age yielded age-by-treatment-by-DRD4 interaction effects similar to those of 
CSIADJ, but none reached significance according to the multiple comparisons threshold (p=0.013, 





We investigated associations between stimulant treatment and striatal, frontal, and 
hippocampal volumes, and potential moderating effects of genotype and age, in children, 
adolescents, and young adults with ADHD. There were three main findings. First, stimulant 
treatment was not associated with striatal volume. Second, associations between stimulant 
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age. Associations were particularly pronounced in carriers of the DRD4 7R-allele at younger age, 
and were not accounted for by clinical and/or demographic confounders. Finally, irrespective of 
stimulant treatment, left striatal volume was reduced in carriers of one DAT1 10-6 risk allele 
compared to 10-6 homozygotes.  
We had hypothesized that stimulant treatment would be associated with more normative 
regional brain volumes, especially at younger age and in carriers of DAT1 10-6 and/or DRD4 7R 
risk alleles. Striatal volumes were not altered in participants with ADHD compared to controls, 
which, as previously reported in the our sample,3 may be due to volume reduction becoming less 
apparent at late-adolescent/early-adult age.1,4 Furthermore, we found no indication of stimulant 
treatment positively affecting striatal volume, as had been suggested by two meta-analyses both 
including only slightly more participants compared to the current sample.1,4 In contrast, our 
findings in the frontal cortex are consistent with age- and genotype-specific volumetric changes 
toward more normative levels after stimulant treatment. Frontal cortex volume was reduced in 
participants with ADHD compared to controls. In carriers of the DRD4 7R-allele, more intense 
stimulant treatment (either higher dose or longer duration) was associated with increased frontal 
cortex volumes at younger age. Such associations were not observed at older age, or in 
individuals not carrying the 7R-allele.  
Although our observational study design is inconclusive as to whether associations 
between stimulant treatment and frontal cortex volume constitute treatment effects, it is 
worthwhile to explore possible underlying mechanisms. The frontal cortex of DRD4 7R-carriers 
may at younger age, e.g., in late childhood when D4 receptor density in the frontal cortex peaks,48 
exhibit postsynaptic characteristics allowing for long-term neural plasticity in the event of 
exposure to stimulants. Long-term plasticity occurs only when tonic dopamine levels, maintained 
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neither too high nor too low.49 Fine-tuning of tonic dopamine levels is managed through 
inhibitory feedback mechanisms involving D4 receptors50 and has been associated with DRD4 
7R-carriership.51 Thus, early age, presence of the 7R-allele, and stimulant treatment may together 
adjust tonic dopamine levels to enable structural remodeling in the frontal cortex. Alternatively, 
the older participants may represent a specific patient population (i.e., persistent ADHD) that 
could be less likely to show genotype-by-treatment interaction effects, compared to the 
potentially more mixed younger group (i.e., this group likely includes participants who will remit 
during adolescence). This interpretation is plausible given the cross-sectional nature of our study. 
As another possibility, brain changes in 7R-carriers may result from an enhanced acute frontal 
cortex response to stimulant treatment at younger age, increasing the likelihood of long-term 
changes in this group. Finally, the lack of association between treatment and brain changes at 
later age may result from treatment discontinuation, i.e., lasting treatment effects may require 
ongoing treatment. Post-hoc analysis did not indicate significant contributions of current 
treatment (y/n) or time since last treatment, but individual and combined effects of various 
treatment parameters can only be disentangled in rigorously designed intervention studies. Note 
that speculations about potential micro-level mechanisms can only be tested using alternative 
approaches (e.g., animal or radio-ligand studies). Moreover, our findings await replication in an 
independent sample.  
Similar to the frontal cortex findings, the association between stimulant treatment and left 
hippocampal volume was strongest in DRD4 7R-carriers and at younger age. Notably, there were 
no case-control differences in hippocampal volume. In 7R-carriers, especially at younger age, 
hippocampal volume appeared to deviate from the controls with more intense stimulant 
treatment. Similar but non-significant effects were found for treatment duration, non-adjusted 
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CSIADJ. Treatment-related hippocampal volume reduction has previously been reported in 
individuals with ADHD.52,53 Further investigation of long-term stimulant treatment effects on 
hippocampal development is warranted. 
A final noteworthy finding was the larger striatal volume in DAT1 10-6 risk allele 
homozygotes compared to carriers of only one risk allele. At trend level, the non-carriers also 
differed from the heterozygotes, but not from the homozygotes, which could indicate a non-linear 
association (0 copies > 1 copy < 2 copies). Other studies have reported smaller striatal volumes in 
3’UTR VNTR 10-repeat homozygotes compared to heterozygotes and/or non-carriers.12,54 This 
seems at variance with the current findings, but note that these studies classified participants 
based on the 3’-UTR VNTR alone rather than on DAT1 haplotype. Moreover, non-carriers were 
not examined in these previous studies. In follow-up analyses we found no association between 
striatal volume and the 3’-UTR 10/10 polymorphism alone (data not shown). Participants’ age 
may also contribute to divergent findings; comparing striatal volumes of children/adolescents 
(including the current sample) and adults with different DAT1 haplotypes, our group found that 
the 9-6 variant was associated with larger striatal volume in adults but not adolescents with 
ADHD.55 It is noteworthy that in the current study we did not find this gene-by-age interaction 
effects on striatal volume, nor was the 9-6 variant associated with striatal volume (data not 
shown). Our finding of a putative non-linear pattern should not be over-interpreted; it did not 
reach our adjusted significance level, was not hypothesized a priori, and could not be related to 
existing literature. Replication of the DAT1 haplotype findings in an independent sample is 
needed. 
Essential features of the current study could not have been achieved in a randomized 
controlled design. Our sample covered a wide treatment- and age-range, allowing for the study of 
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potential treatment effects occurring only after multiple years of treatment, and/or occurring long 
after treatment had been discontinued. Notwithstanding, the current observational design brings 
caveats regarding causal interference. Unmeasured pre-existing factors associated with treatment 
(e.g., pre-treatment symptom severity) or simultaneously occurring events (e.g., concurrent 
behavioral treatment) may have contributed to the observed associations. Second, age effects 
should be interpreted with appropriate caution given our cross-sectional design. Participants 
included at older age may represent a different population (e.g., persistent ADHD) compared to 
those included at younger age. A longitudinal study design is required to allow conclusions about 
developmental effects. Finally, we wish to emphasize that clinical application of our findings of 
small effect size is still several steps away, e.g., behavioral correlates of subtle brain changes 
require further investigation.  
In sum, we investigated associations between stimulant treatment and regional brain 
volumes, and potential moderating effects of age and genotype, in a cross-sectional ADHD 
cohort. We found that frontal cortex volume was associated with stimulant treatment in carriers 
of the DRD4 7R-allele at younger age, possibly suggesting normalizing effects in these 
participants. Striatal volume was associated with DAT1 haplotype, but not with treatment. We 
propose that neural sensitivity to long-term treatment effects may arise from genotype- and age-
specific characteristics of postsynaptic dopamine receptors, allowing for long-term plasticity 
when exposed to stimulant treatment. The clinical relevance of subtle brain changes of small 
effect size is expected to be modest and requires further investigation; nevertheless, our findings 
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Table 1.  
Demographic and clinical characteristics of the ADHD sample, and their associations with 
stimulant treatment. 
    Association with CSIADJa 
 n %       F    r  
Gender=male 219 69.3  29.8 *   
Site=Nijmegen 178 56.3  7.0    
Age (M,SD) 17.2 3.4    -0.01  
IQ (M,SD) 96.1 16.1    -0.01  
Socio-economic status (M,SD) 11.5 2.3    0.04  
CPRS inattention (M,SD) 64.4 14.3    0.05  
CPRS hyperactivity/impulsivity (M,SD)  68.2 17.4    0.05  
DAT1 10-6 risk allele    3.6    
0 copies (non-carrier) 20 6.4      
1 copy (heterozygote) 134 42.7      
2 copies (homozygote) 160 51.0      
DRD4 7R risk allele    1.2    
0 copies (non-carrier) 208 65.8      
1 or 2 copies (carrier)  108 34.2      
ADHD-type    10.9 *   
Inattentive 141 44.6      
Hyperactive/impulsive  37 11.7      
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Comorbidity (any) 111 35.1  1.4    
History of stimulant treatment (y/n) 278 88.0  N/A    
Treatment duration in years (M,SD) 4.1 3.3    0.713 * 
Start age (M,SD) 8.5 2.8    -0.496b * 
Years since last treatment (M,SD) 1.5 2.3    -0.417b * 
Currently on active treatment 148 46.8  59.8b *   
History of atomoxetine treatment (y/n) 39 12.3  0.5    
History of non-stimulant medication (y/n) 65 20.6  2.2    
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Table 2.  
Regression weights of treatment, genotype, and treatment-by-genotype, and their interactions with 
age and age2. Parameters of covariates and lower-level terms are available online. 
 Striatum Frontal cortex Hippocampus 
 L R L R L R 
Initial model       
CSIADJa 0.073 0.051 0.040 0.031 0.067 0.002 
DAT10-COPIES 0.162 0.060     
DAT11-COPY -0.252* -0.186     
DRD4NON-CARRIER   0.007 0.236 -0.001 0.023 
CSIADJ x DAT10-COPIES -0.170 -0.086     
CSIADJ x DAT11-COPY -0.111 -0.081     
CSIADJ x DRD4NON-CARRIER   -0.458 -0.240 -0.085 -0.008 
Age-interaction model       
Age x CSIADJ x DAT10-COPIES ns ns     
Age x CSIADJ x DAT11-COPY ns ns     
Age x CSIADJ x DRD4NON-CARRIER   0.756 0.458 0.158* ns 
Age2 x CSIADJ x DAT10-COPIES ns ns     
Age2 x CSIADJ x DAT11-COPY ns ns     
Age2 x CSIADJ x DRD4NON-CARRIER   -1.717* -2.030* ns ns 
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Figure 1. 
Participants’ stimulant treatment trajectories. Daily stimulant dose (y-axis) is plotted as a function 
of age in years (x-axis), between age=0 and age at study participation. Participants are stratified 
in age quartiles; bold markers represent the average daily dose across participants within each 
quartile. Age at study participation was significantly associated with treatment duration 
(r=0.202), start age (r=0.298), and time since last treatment (r=0.377), and participants on active 
treatment are younger (M=15.9) compared to participants who had discontinued treatment 
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Figure 2.  
Three-way interaction effects between CSIADJ, DRD4 genotype, and age or age2, on volumes of 
the left and right frontal cortex and left hippocampus. For display, volumes based on the 
regression function are estimated at younger age (age=1SD below the mean, age2=-1SD*-1SD) 
and at older age (age=1SD above the mean, age2=+1SD*+1SD), and separately for carriers and 
non-carriers of the DRD4 7R-risk allele. In the absence of stimulant treatment in control 
participants, estimated average volume for controls is presented as a dashed horizontal line (+/- 
1SD shaded). CSIADJ=age-adjusted cumulative stimulant intake; mg/y = milligrams per year; 
 
